What is Contraline?
Founded in 2015, Contraline operates at the intersection of reproductive health and advanced materials science. The company is primarily focused on the development of ADAM, a groundbreaking medical device designed to offer a reversible, non-hormonal alternative to traditional contraceptive methods. By leveraging proprietary hydrogel technology, Contraline aims to address a critical gap in the global reproductive health market. The company's strategic trajectory has evolved from early-stage research and development to a more mature phase, supported by a diverse syndicate of life science investors and specialized healthcare venture firms.
How much funding has Contraline raised?
Contraline has raised a total of $113.7M across 5 funding rounds:
Angel/Seed
$2.3M
Series A
$10.7M
Other Financing Round
$1M
Other Financing Round
$7.2M
Series B
$92.5M
Angel/Seed (2017): $2.3M, investors not publicly disclosed
Series A (2021): $10.7M led by Smith Ventures, Founders Fund, Metaplanet, MBX Capital, Graphene Ventures, ShangBay Capital, and Rhia Ventures
Other Financing Round (2022): $1M supported by Male Contraceptive Initiative
Other Financing Round (2022): $7.2M featuring GV and Rhia Ventures
Series B (2026): $92.5M backed by BVF Partners, GV, Lumira Ventures, and RA Capital Management
Key Investors in Contraline
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments with a focus on long-term value creation.
GV
GV is a global venture capital firm that invests across multiple stages and sectors, with a strong emphasis on life sciences and frontier technology innovations.
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, partnering with mission-driven entrepreneurs to develop and commercialize impactful medical devices and biotherapeutics.
What's next for Contraline?
Following this major enterprise-level funding, Contraline is expected to prioritize the clinical validation and regulatory pathway for its ADAM device. The capital deployment will likely focus on scaling manufacturing capabilities and expanding the clinical trial infrastructure necessary to bring this novel technology to market. As the company transitions into a more advanced lifecycle stage, the focus will shift toward establishing commercial viability and navigating the complex regulatory landscape governing medical devices in the reproductive health sector. The continued support from high-profile life science investors suggests a robust roadmap for long-term growth and market penetration.
See full Contraline company page
